Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/31883| Title: | Targeting toll-like receptors for drug development: A summary of commercial approaches. | Authors: | Gearing A.J.H. | Institution: | (Gearing) Biocomm Squared, Monash Institute of Medical Research, Monash University, Clayton, Vic., Australia (Gearing) Biocomm Squared, Monash Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia | Issue Date: | 17-Oct-2012 | Copyright year: | 2007 | Publisher: | Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom) | Place of publication: | United Kingdom | Publication information: | Immunology and Cell Biology. 85 (6) (pp 490-494), 2007. Date of Publication: August 2007. | Abstract: | Toll-like receptors (TLRs) play a fundamental role in recognizing infectious and noxious agents as well as products of tissue damage. They are capable of initiating both protective and damaging inflammatory and immune responses. Several biotechnology and pharmaceutical companies have programmes to develop new drugs that are either: agonists of TLRs to enhance immune responses against tumours and infectious agents, or to correct allergic responses; or antagonists designed to reduce inflammation due to infection or autoimmune disease. This article reviews the commercial approaches being undertaken to develop new TLR drugs. © 2007 Australasian Society for Immunology Inc. All rights reserved. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/sj.icb.7100102 | PubMed URL: | 17667933 [http://www.ncbi.nlm.nih.gov/pubmed/?term=17667933] | ISSN: | 0818-9641 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/31883 | Type: | Review | Subjects: | human *immune response infection inflammation kidney carcinoma lung non small cell cancer/dt [Drug Therapy] melanoma multiple sclerosis/dt [Drug Therapy] psoriasis/dt [Drug Therapy] rheumatoid arthritis/dt [Drug Therapy] sepsis/dt [Drug Therapy] signal transduction tissue injury tumor cathelicidin/dv [Drug Development] cathelicidin antimicrobial peptide LL 37 CpG 7909/dv [Drug Development] CpG 7909/dt [Drug Therapy] flagellin heat shock protein 10/dt [Drug Therapy] imiquimod/ct [Clinical Trial] imiquimod/dv [Drug Development] imiquimod/tp [Topical Drug Administration] influenza vaccine/cb [Drug Combination] influenza vaccine/dt [Drug Therapy] influenza vaccine/pd [Pharmacology] lipid A derivative/dt [Drug Therapy] lipid A derivative/pd [Pharmacology] *rituximab/cb [Drug Combination] *toll like receptor toll like receptor 7/dv [Drug Development] unclassified drug Wart virus vaccine/ct [Clinical Trial] Wart virus vaccine/dt [Drug Therapy] ana 773 ana 975 ave 0675 ave 7279 cationic lipid/dv [Drug Development] cq 07001/ct [Clinical Trial] cq 07001/dv [Drug Development] crx 675/ct [Clinical Trial] crx 675/dt [Drug Therapy] crx 675/tp [Topical Drug Administration] e 5564 eritoran/ct [Clinical Trial] eritoran/dv [Drug Development] eritoran/dt [Drug Therapy] eritoran/pd [Pharmacology] Flagellin huha Flagellin hum2e heplislav/dv [Drug Development] imo 2055/dv [Drug Development] imo 2055/dt [Drug Therapy] iph 31xx/dv [Drug Development] iph 32xx/dv [Drug Development] mct 465/dv [Drug Development] ph 31xx ph 32xx resatorvid/dv [Drug Development] sotorabine/ct [Clinical Trial] tak 242 tolamba/ct [Clinical Trial] tolamba/dv [Drug Development] toll like receptor 3 agonist toll like receptor 9 agonist/cb [Drug Combination] toll like receptor 9 agonist/dv [Drug Development] toll like receptor 9 agonist/dt [Drug Therapy] toll like receptor 9 agonist/pd [Pharmacology] vaximmune/ct [Clinical Trial] vaximmune/dv [Drug Development] review immunity actinic keratosis/dt [Drug Therapy] allergic reaction allergic rhinitis/dt [Drug Therapy] autoimmune disease basal cell carcinoma/dt [Drug Therapy] biotechnology clinical trial colorectal cancer/dt [Drug Therapy] condyloma/dt [Drug Therapy] cutaneous T cell lymphoma *drug synthesis drug targeting drug targeting human *immune response immunity infection inflammation kidney carcinoma lung non small cell cancer / drug therapy melanoma multiple sclerosis / drug therapy psoriasis / drug therapy review rheumatoid arthritis / drug therapy sepsis / drug therapy signal transduction tissue injury tumor allergic rhinitis / drug therapy actinic keratosis / drug therapy allergic reaction autoimmune disease basal cell carcinoma / drug therapy biotechnology clinical trial colorectal cancer / drug therapy condyloma / drug therapy cutaneous T cell lymphoma *drug synthesis |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.